Tenaya Therapeutics Outperform Rating Reiterated at Lifesci Capital
TNYA Stock | USD 3.66 0.08 2.23% |
About 57% of Tenaya Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Tenaya Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Tenaya Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Tenaya Therapeutics stock news signals to limit their universe of possible portfolio assets.
Tenaya |
Tenaya Therapeutics s stock had its outperform rating reissued by stock analysts at Lifesci Capital in a research report issued to clients and investors on Tuesday, PriceTargets.com reports. Lifesci Capital also issued estimates for Tenaya Therapeutics Q3 2023 earnings at EPS, Q4 2023 earnings at EPS and FY2023 earnings
Read at thelincolnianonline.com
Tenaya Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Tenaya Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tenaya Therapeutics Fundamental Analysis
We analyze Tenaya Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tenaya Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tenaya Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Tenaya Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Tenaya Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tenaya Therapeutics stock to make a market-neutral strategy. Peer analysis of Tenaya Therapeutics could also be used in its relative valuation, which is a method of valuing Tenaya Therapeutics by comparing valuation metrics with similar companies.
Peers
Tenaya Therapeutics Related Equities
DMAC | DiaMedica Therapeutics | 5.23 | ||||
VCNX | Vaccinex | 1.50 | ||||
VCYT | Veracyte | 1.23 | ||||
VANI | Vivani Medical | 0.78 | ||||
DNTH | Dianthus Therapeutics | 0.77 | ||||
VCEL | Vericel Corp | 0.63 | ||||
DOMH | Dominari Holdings | 1.20 | ||||
DNLI | Denali Therapeutics | 2.53 | ||||
EQ | Equillium | 4.11 | ||||
VALN | Valneva SE | 6.16 |
Complementary Tools for Tenaya Stock analysis
When running Tenaya Therapeutics' price analysis, check to measure Tenaya Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenaya Therapeutics is operating at the current time. Most of Tenaya Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenaya Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenaya Therapeutics' price. Additionally, you may evaluate how the addition of Tenaya Therapeutics to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |